<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0603256996
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CARPAZIO 600 MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OXCARBAZEPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        74.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AF02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What CARPAZIO is<br />CARPAZIO contains the active substance oxcarbazepine.<br />CARPAZIO belongs to a group of medicines called anticonvulsants or antiepileptics.<br />What CARPAZIO is used for<br />Medicines such as CARPAZIO are the standard treatment for epilepsy.<br />Epilepsy is a brain disorder that causes people to have recurring seizures and convulsions.<br />Seizures happen because of a temporary fault in the brain&rsquo;s electrical activity. Normally brain<br />cells coordinate body movements by sending out signals through the nerves to the muscles in an<br />organized, orderly way. In epilepsy, brain cells send out too many signals in a disorderly fashion.<br />The result can be uncoordinated muscular activity that is called an epileptic seizure.<br />CARPAZIO is used to treat partial seizures with or without secondarily generalized tonic-clonic<br />seizures. Partial seizures involve a limited area of the brain but may spread to the whole brain<br />and may cause a generalized tonic-clonic seizure. There are two types of partial seizures: simple<br />and complex. In simple partial seizures, the patient remains conscious, whereas in complex<br />partial seizures, patient&rsquo;s consciousness is altered.CARPAZIO works by keeping the brain&rsquo;s &ldquo;over-excitable&rdquo; nerve cells under control. This<br />suppresses or reduces the frequency of such seizures.<br />CARPAZIO can be used alone or in combination with other antiepileptic medicines.<br />Usually, the doctor will try to find the one medicine that works best for you or for your child.<br />However, with more severe epilepsy, a combination of two or more medicines may be needed to<br />control seizures.<br />CARPAZIO is for use in adults and in children of 6 years of age and above.<br />If you have any questions about how CARPAZIO works or why this medicine has been<br />prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all your doctor&rsquo;s instructions carefully, even if they differ from the general information<br />contained in this leaflet.<br />Monitoring during your treatment with CARPAZIO<br />Before and during your treatment with CARPAZIO, your doctor may perform blood tests to<br />determine the dose for you. Your doctor will tell you when to have the tests.<br />Do not take CARPAZIO<br />&bull; If you are allergic to oxcarbazepine or to any other ingredients of CARPAZIO tablets (listed<br />in section 6 or if you are allergic to eslicarbazepine.<br />If this applies to you, tell your doctor before taking CARPAZIO. If you think you may be<br />allergic, ask your doctor for advice.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking CARPAZIO:<br />&bull; If you have ever shown unusual sensitivity (rash or any other signs of allergy) to<br />carbamazepine or to any other medicines. If you are allergic to carbamazepine, the chances<br />are approximately 1 in 4 (25 %) that you could also have an allergic reaction to<br />oxcarbazepine (CARPAZIO).<br />&bull; If you have a kidney disease.<br />&bull; If you have a serious liver disease.<br />&bull; If you are taking diuretics (medicines used to help the kidneys get rid of salt and water by<br />increasing the amount of urine produced).<br />&bull; If you have a heart disease, shortness of breath and/or swelling of the feet or legs due to<br />fluid buildup.<br />&bull; If your blood level of sodium is low as shown by blood tests (see section 4 Possible side<br />effects).<br />&bull; If you are a woman taking a hormonal contraceptive, such as the birth-control pill,<br />CARPAZIO may stop your contraceptive from working. Use a different or extra (nonhormonal)<br />method of contraception while taking CARPAZIO. This should help to prevent an&nbsp;unwanted pregnancy. Tell your doctor immediately if you get irregular vaginal bleeding or<br />spotting. If you have any questions about this, ask your doctor or health professional.<br />The risk of serious skin reactions in patients of Han Chinese or Thai origin associated with<br />carbamazepine or chemically related compounds may be predicted by testing a blood sample of<br />these patients. Your doctor should be able to advise if a blood test is necessary before taking<br />oxcarbazepine.<br />If you develop any of the following symptoms after starting CARPAZIO, tell your doctor<br />immediately or go to the emergency department at your nearest hospital:<br />&bull; If you experience an allergic reaction after starting CARPAZIO. Symptoms include<br />swelling of lips, eyelids, face, throat, mouth, or sudden breathing problems, fever with<br />swollen glands, rash or skin blistering.<br />&bull; If you notice symptoms of hepatitis, such as jaundice (yellowing of skin or the whites of the<br />eyes).<br />&bull; If you experience an increase in the frequency of seizures. This is particularly important for<br />children but may also occur in adults.<br />&bull; If you notice possible symptoms of blood disorders such as tiredness, being short of breath<br />when exercising, looking pale, headache, chills, dizziness, frequent infections leading to<br />fever, sore throat, mouth ulcers, bleeding or bruising more easily than normal, nose bleeds,<br />reddish or purplish patches, or unexplained blotches on the skin.<br />&bull; A small number of people being treated with antiepileptics such as CARPAZIO have had<br />thoughts of harming or killing themselves. If at any time you have these thoughts,<br />immediately contact your doctor.<br />&bull; If you have a fast or unusually slow heartbeat.</p><p>Children and adolescents<br />In children, your doctor may recommend thyroid function monitoring before therapy and during<br />therapy.<br />Other medicines and CARPAZIO<br />Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.<br />This applies especially to:<br />&bull; Hormonal contraceptives, such as the pill (see Warnings and precautions).<br />&bull; Other antiepileptic and enzyme inducing medicines, such as carbamazepine, phenobarbital,<br />phenytoin or lamotrigine and rifampicin.<br />&bull; Medicines that reduce the level of sodium in your blood, such as diuretics (used to help the<br />kidneys get rid of salt and water by increasing the amount of urine produced), desmopressin<br />and non-steroidal anti-inflammatory drugs, such as indomethacin.<br />&bull; Lithium and monoamine oxidase inhibitors (medicines used to treat mood swings and some<br />types of depression).<br />&bull; Medicines that control the body&rsquo;s immune system, such as ciclosporin and tacrolimus.</p><p>Taking CARPAZIO with food and drink<br />CARPAZIO can be taken with or without food.<br />Alcohol may increase the sedative effects of CARPAZIO. Avoid alcohol as much as possible<br />and ask your doctor for advice.<br />Pregnancy, breast-feeding and fertility<br />Pregnancy<br />If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor<br />or pharmacist for advice before taking this medicine.<br />It is important to control epileptic seizures during pregnancy. However, there may be a risk to<br />your baby if you take antiepileptic medicines during pregnancy. Your doctor will tell you the<br />benefits and potential risks involved and help you to decide whether you should take<br />CARPAZIO.<br />Do not stop your treatment with CARPAZIO during pregnancy without first checking with your<br />doctor.<br />Breast-feeding<br />You should not breast-feed while taking CARPAZIO. The active substance in CARPAZIO<br />passes into breast milk.<br />This could cause side effects for breast-fed babies. Ask your doctor or pharmacist for advice<br />before taking this medicine while you are breast-feeding.<br />Driving and using machines<br />CARPAZIO may make you feel sleepy or dizzy, or may cause blurred vision, double vision, lack<br />of muscle coordination or a depressed level of consciousness, especially when starting treatment<br />or increasing the dose.<br />It is important to discuss with your doctor whether you can drive a vehicle or operate machines<br />while taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take CARPAZIO exactly as your doctor or pharmacist has told you, even if this differs<br />from the information given in this leaflet. Check with your doctor or pharmacist if you are not<br />sure.<br />How much to take<br />Dose for adults<br />&bull; The usual starting dose of CARPAZIO for adults (including elderly patients) is 600 mg per<br />day.<br />&bull; Take one 300 mg tablet twice daily or two 150 mg tablets twice daily.<br />&bull; Your doctor may increase the dose gradually to find the best dose for you. The best results<br />are usually with doses between 600 and 2,400 mg per day.<br />&bull; If you take another antiepileptic medicine, the dose is the same.</p><p>&bull; If you have kidney disease (with impaired kidney function), the starting dose is half the usual<br />starting dose.<br />&bull; If you have severe liver disease, your doctor may adjust your dose.<br />Dose for children<br />CARPAZIO can be taken by children aged 6 years or above.<br />The dosage for children depends on their weight.<br />&bull; The starting dose is 8 to 10 milligrams per kilogram of bodyweight per day given in two<br />divided doses.<br />For example, a 30-kg child would start treatment with 150 mg oxcarbazepine twice daily.<br />&bull; Your doctor may increase the dose gradually to find the best dose for your child. The best<br />results are usually with a dose of 30 milligrams per kilogram of bodyweight per day. The<br />maximum dose for a child is 46 milligrams per kilogram of bodyweight per day.<br />How to take CARPAZIO<br />&bull; Swallow the tablets with a little water.<br />&bull; If necessary, the tablets can be broken in half to help swallow them. Do not break the tablets<br />to take only half of the dose. The score line was not designed for dividing the tablet into<br />equal doses.<br />&bull; For small children who cannot swallow tablets, or who cannot be given the necessary dose in<br />tablet form, oxcarbazepine is available as an oral suspension.</p><p>When and for how long to take CARPAZIO<br />Take CARPAZIO twice a day, every day, at about the same time of day, unless the doctor tells<br />you otherwise.<br />This will have the best effect on controlling epilepsy. It will also help you to remember when to<br />take the tablet(s).<br />Your doctor will tell you how long your or your child&rsquo;s treatment with CARPAZIO will last. The<br />length of treatment will depend on your or your child&rsquo;s seizure type. Treatment may be needed<br />for many years to control the seizures. Do not change the dose or stop treatment without talking<br />to your doctor.<br />If you take more CARPAZIO than you should<br />If you have taken more tablets than your doctor prescribed, contact the nearest hospital or your<br />doctor immediately. Symptoms of overdose with CARPAZIO may include:<br />&bull; Drowsiness, dizziness, problems with coordination and/or involuntary movement of the eyes,<br />muscular twitching or significant worsening of convulsions, headache, loss of consciousness,<br />coma .<br />&bull; Feeling sick (nausea), being sick (vomiting), increased uncontrolled movements.<br />&bull; Lethargy, double vision, narrowing of black part of the eye, blurred vision.<br />&bull; Tiredness.<br />&bull; Short and shallow breathing (respiratory rate depression).</p><p>&bull; Irregular heartbeat (QTc prolonged interval).<br />&bull; Trembling, headache, coma, decreased consciousness, uncontrollable movements of mouth,<br />tongue and limbs.<br />&bull; Aggression, agitation, confusion.<br />&bull; Low blood pressure.<br />&bull; Breathlessness.<br />If you forget to take CARPAZIO<br />If you have forgotten one dose, take it as soon as you remember. However, if it is time for your<br />next dose, do not take the missed dose. Go back to your regular dosing timetable. Do not double<br />the dose at any time.<br />If you are unsure or have forgotten to take several doses, contact your doctor.<br />If you stop taking CARPAZIO<br />Do not stop taking your medicine unless your doctor tells you to.<br />To prevent sudden worsening of your seizures, never discontinue your medicine abruptly.<br />If your treatment is stopped, it should be done gradually as instructed by your doctor.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, CARPAZIO can cause side effects, although not everybody gets them.<br />Tell your doctor immediately or go to the emergency department at your nearest hospital if you<br />get any of the following side effects:<br />The following are signs of very rare (may affect up to 1 in 10,000 people), but potentially serious<br />side effects that may require urgent medical treatment. The doctor will also decide whether<br />CARPAZIO has to be stopped immediately and how to continue further medical care.<br />&bull; Swelling of the lips, eyelids, face, throat or mouth, accompanied by difficulty in breathing,<br />speaking or swallowing (signs of anaphylactic reactions and angioedema) or other signs of<br />hypersensitivity reactions such as skin rash, fever, and pain in the muscles and joints.<br />&bull; Severe blistering of the skin and/or mucous membranes of the lips, eyes, mouth, nasal<br />passages or genitals (signs of serious allergic reaction including Lyell&rsquo;s syndrome, Stevens-<br />Johnson syndrome and erythema multiforme).<br />&bull; Tiredness, shortness of breath when exercising, looking pale, headache, chills, dizziness,<br />frequent infections leading to fever, sore throat, mouth ulcers, bleeding or bruising more<br />easily than normal, nose bleeds, reddish or purplish patches, or unexplained blotches on the<br />skin (signs of a decrease in the number of blood platelets or decrease in the number of blood<br />cells).<br />&bull; Red blotchy rash mainly on face which may be accompanied by fatigue, fever, feeling sick<br />(nausea) or loss of appetite (signs of systemic lupus erythematosus).<br />&bull; Lethargy, confusion, muscle twitching or significant worsening of convulsions (possible<br />symptoms of low sodium levels in the blood) (see Warnings and precautions).</p><p>&bull; Flu-like symptoms with jaundice (yellowing of the skin or the whites of the eyes) (signs of<br />hepatitis).<br />&bull; Severe upper stomach (abdominal) pain, being sick (vomiting), loss of appetite (signs of<br />inflammation of the pancreas).<br />&bull; Weight gain, tiredness, hair loss, muscle weakness, feeling cold (signs of under active<br />thyroid gland).<br />Tell your doctor as soon as possible if you get any of the following side effects, they may<br />require medical attention:<br />Common (may affect up to 1 in 10 people):<br />&bull; Trembling; coordination problems; involuntary movement of the eyes; anxiety and<br />nervousness; depression; mood swing; rash.<br />Very rare (may affect up to 1 in 10,000 people):<br />&bull; Irregular heartbeat or a very fast or slow heart rate.<br />Other side effects that may occur:<br />These are usually mild to moderate side effects of CARPAZIO. Most of these effects are<br />transient and usually diminish over time.<br />Very common (may affect more than 1 in 10 people):<br />&bull; Tiredness; headache; dizziness; drowsiness; feeling sick (nausea); being sick (vomiting);<br />double vision.<br />Common (may affect up to 1 in 10 people):<br />&bull; Weakness; memory disturbances; impaired concentration; apathy; agitation; confusion;<br />blurred vision; visual disturbance; constipation; diarrhoea; stomach (abdominal) pain; acne;<br />hair loss, balance disturbances, weight increased.<br />Uncommon (may affect up to 1 in 100 people):<br />&bull; Hives. You may also have raised levels of liver enzymes while taking CARPAZIO.<br />Not known (frequency cannot be estimated from the available data):<br />&bull; High blood pressure, speech disorder.<br />&bull; There have been reports of bone disorders including osteopenia and osteoporosis (thinning of<br />the bone) and fractures. Check with your doctor or pharmacist if you are on long-term<br />antiepileptic medication, have a history of osteoporosis or take steroids.</p><p>Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible<br />side effects not listed in this leaflet. You can also report side effects directly via The National<br />Pharmacovigilance and Drug Safety Centre (NPC). By reporting side affects you can help<br />provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30&deg;C.<br />&bull; Do not use this medicine after the expiry date which is stated on the blister and the outer<br />carton. The expiry date refers to the last day of that month.<br />&bull; Do not use CARPAZIO if you notice that the pack is damaged or shows signs of tampering.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist<br />how to dispose of medicines you no longer use. These measures will help to protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance of CARPAZIO is oxcarbazepine.<br />&bull; CARPAZIO 150 MG FILM-COATED TABLETS<br />Each film-coated tablet contains 150 mg oxcarbazepine.<br />&bull; CARPAZIO 300 MG FILM-COATED TABLETS<br />Each film-coated tablet contains 300 mg oxcarbazepine.<br />&bull; CARPAZIO 600 MG FILM-COATED TABLETS<br />Each film-coated tablet contains 600 mg oxcarbazepine.<br />&bull; The other ingredients are:<br />Tablet core: Avicel 101, Crospovidone NF, Povidone 30, Avicel 102, Colloidal Silicon<br />Dioxide and Magnesium Stearate.<br />Tablet coating: Opadry II 85F43120 Orange and Purified Water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The 150 mg tablet is a yellow orange color, capsule shaped, film-coated tablet engraved with
"230" on one side and plain on the other side.
The 300 mg tablet is a yellow orange color, capsule shaped, film-coated tablet engraved with
"231" on one side and plain on the other side.
The 600 mg tablet is a yellow orange color, capsule shaped, film-coated tablet engraved with
"232" on one side and plain on the other side.
The film-coated tablets are available in blister packs containing 50 tablets divided into 5 blisters
for both strengths.
CARPAZIO film-coated tablets come in three strengths 150 mg, 300 mg, 600 mg.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO<br />Al-Qassim Pharmaceutical Plant<br />Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in October 2020.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هو كاربازيو<br />يحتوي كاربازيو على المادة الفعالة أوكسكاربازيبين.<br />ينتمي كاربازيو إلى المجموعة الدوائية التي تسمي مضادات التشنج أو مضادات الصرع.<br />فيم يستخدم كاربازيو<br />الأدوية مثل كاربازيو تمثل العلاج الأساسي في علاج الصرع .<br />الصرع هو اضطراب في المخ يتسبب في تكرار النوبات والتشنجات. النوبات المرضية تحدث بسبب خطأ مؤقت في النظام<br />الكهربي للمخ. عادة ما تقوم خلايا المخ بتنسيق حركات الجسم عن طريق إرسال إشارات عبر الأعصاب إلى العضلات بشكل<br />منتظم ومرتب. في حالة الصرع، ترسل خلايا المخ الكثير من الإشارات بطريقة غير منضبطة. ومن الممكن أن تكون النتيجة<br />هي نشاط عضلي غير منظم والذي يسمي نوبة الصرع .<br />كاربازيو يستخدم في علاج نوبات الصرع الجزئي المصاحبة أو غير المصاحبة بنوبات توتريه ارتجاجية عامة. الصرع<br />الجزئي يشمل جزء محدود في المخ، ولكن من الممكن أن ينتشر إلى كل المخ ومن الممكن أن يتسبب في نوبات توتريه&nbsp;ارتجاجية عامة. هناك نوعان من النوبات الجزئية: البسيطة والمعقدة. في النوبات الجزئية البسيطة، يظل المريض واعيا، بينما<br />في النوبات الجزئية المعقدة، يتغير وعي المريض .<br />كاربازيو يعمل على الحفاظ على خلايا المخ العصبية &quot;شديدة الاستثارة&quot; تحت السيطرة. مما يضع حدا أو يقلل معدل تكرار<br />النوبات.<br />كاربازيو يمكن تناوله بمفرده أو بالإضافة إلى أدوية علاج صرع أخري.<br />عادة ما يحاول الطبيب إيجاد علاج واحد أمثل لك أو لطفلك. بينما مع حالات الصرع الصعبة، من الممكن أن نحتاج إلى تناول<br />نوعين أو أكثر من الأدوية للسيطرة على النوبات.<br />يستخدم كاربازيو في البالغين والأطفال من 6 سنوات فيما أكبر.<br />اسأل طبيبك إذا كانت لديك أي أسئلة حول كيفية عمل كاربازيو أو عن سبب وصفه لك.<br />2</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم باتباع كل تعليمات الطبيب بحرص، حتى ولو اختلفت عن التعليمات العامة المذكورة في النشرة.<br />المتابعة أثناء العلاج ب كاربازيو<br />قبل وأثناء العلاج ب كاربازيو، قد يقوم طبيبك بإجراء اختبارات الدم لتحديد الجرعة لك. سيخبرك طبيبك بموعد إجراء<br />الفحوصات.<br />لا تتناول كاربازيو إذا كان<br />&bull; لديك حساسية من مادة أوكسكاربازيبين أو أي من المكونات الأخرى لأقراص كاربازيو )المذكورة في الفقرة 6( أو إذا كان<br />لديك حساسية من اسليكاربازيبين.<br />إذا كان هذا ينطبق عليك، أخبر طبيبك قبل تناول كاربازيو. إذا كنت تعتقد أنك قد تكون مصابًا بالحساسية، فاستشر طبيبك.<br />المحاذير والاحتياطات<br />تحدث إلى طبيبك أو الصيدلي قبل تناول كاربازيو<br />&bull; إذا ظهرت عليك من قبل حساسية غير عادية )طفح جلدي أو أي من علامات الحساسية الأخرى( ل كاربامازيبين أو أي<br />من الأدوية الأخرى. إذا كانت لديك حساسية من كاربامازيبين، فرص امكانية حدوث تفاعل تحسسي تجاه أوكسكاربازيبين<br />)كاربازيو( قد تصل إلى 1 من كل أربعة مستخدمين للدواء ) 25 %( وبذلك من الممكن أن يكون لديك أيضا حساسية ل<br />أوكسكاربازيبين )كاربازيو(.<br />&bull; إذا كان لديك مرض كلوي.<br />&bull; إذا كان لديك مرض كبدي حاد.<br />&bull; إذا كنت تتناول مدرات للبول )أدوية تستخدم لمساعدة الكلي على التخلص من الأملاح والماء بزيادة كمية انتاج البول(.<br />&bull; إذا كان لديك مرض في القلب، ضيق في التنفس و / أو انتفاخ في الأقدام أو السيقان نتيجة تراكم السوائل.<br />&bull; إذا كان مستوي الصوديوم في الدم منخفضا كما أظهرت تحاليل الدم )انظر قسم 4 الأعراض الجانبية محتملة الحدوث(.<br />&bull; إذا كنتي امرأة تتناول وسائل منع حمل هرمونية، مثل أقراص منع الحمل، من الممكن أن يتسبب كاربازيو في وقف تأثير<br />وسيلة منع الحمل. قومي باستخدام وسيلة منع حمل أخري أو اضافية )غير هرمونية( أثناء تناول كاربازيو. يجب أن<br />يساعدك هذا على منع الحمل غير المرغوب في حدوثه. قومي بإخبار طبيبك على الفور إذا كان لديك نزيف مهبلي غير<br />منتظم أو بقع. إذا كانت لديك أي أسئلة متعلقة بهذا الأمر، قومي باستشارة طبيبك.</p><p>ويمكن توقع خطر حدوث تفاعلات جلدية خطيرة في المرضى ذات الأصول الصينية أو التايلاندية مرتبطة ب تناول<br />كاربامازيبين أو المركبات الكيميائية ذات الصلة عن طريق اختبار عينة من الدم لهؤلاء المرضى. يجب على طبيبك أن<br />يقوم بتقديم المشورة في حالة ضرورة اجراء تحليل دم قبل تناول أوكسكاربازيبين.<br />إذا ظهرت عليك أي من الأعراض التالية بعد البدء في تناول كاربازيو، قم بإ خبار طبيبك على ال فور أو قم بالذهاب إلي قسم<br />الطوارئ في أقرب مستشفى:<br />&bull; إذا كنت تعاني من الحساسية بعد بدء تناول كاربازيو. وتشمل الاعراض تورم الشفتين والجفون والوجه والحلق والفم، أو<br />مشاكل مفاجئة في التنفس، وحمى مع تورم في الغدد، طفح جلدي أو تقرحات في الجلد.<br />&bull; إذا لاحظت ظهور أعراض الالتهاب الكبدي، مثل الصفراء )اصفرار الجلد أو بياض العينين(.<br />&bull; إذا واجهت زيادة في معدل تكرار النوبات. هذا مهم بشكل خاص للأطفال ولكن قد يحدث أيضًا عند البالغين.<br />&bull; إذا لاحظت أعراض محتملة لاضطرابات الدورة الدموية مثل التعب، ضيق في التنفس عند ممارسة التمارين، شحوب،<br />صداع، قشعريرة، دوخة، التهابات متكررة تؤدي إلى حمى، التهاب الحلق، تقرحات الفم، حدوث نزيف أو كدمات بسهولة<br />أكبر من المعتاد، نزيف الأنف، ظهور البقع الحمراء أو الأرجوانية، أو بقع غير مبررة على الجلد.<br />&bull; عدد قليل من الناس الذين يعالجون بتناول مضادات الصرع مثل كاربازيو قد يتولد لديهم أفكار عن إيذاء أو قتل أنفسهم. إذا<br />تولدت لديك في أي وقت هذه الأفكار، اتصل فورا بطبيبك.<br />&bull; إذا كانت لديك ضربات قلب سريعة أو بطيئة على نحو غير عادي.<br />الأطفال والمراهقين<br />قد يوصي طبيبك بمراقبة وظيفة الغدة الدرقية في الأطفال قبل وأثناء العلاج.<br />أدوية أخري وكاربازيو<br />أخبر طبيبك المعالج أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخري .<br />وذلك ينطبق بشكل خاص علي:<br />&bull; موانع الحمل الهرمونية، مثل الأقراص )انظر المحاذير والاحتياطات(.<br />&bull; مضادات الصرع الأخرى، الادوية المحفزة للإنزيمات مثل كاربامازيبين، فينوباربيتال، فينيتوين أو لاموتريجين<br />وريفامبيسين.<br />&bull; الأدوية التي تخفض مستوي الصوديوم في الدم، مثل مدرات البول )التي تستخدم في مساعدة الكلي على طرد الأملاح<br />والماء عن طريق زيادة كمية البول الناتج(، ديسموبريسين والعقاقير غير الستيرويدية المضادة للالتهابات، مثل<br />إندوميثازين.<br />&bull; الليثيوم ومثبطات أحادي أمين الأوكسيديز )الأدوية المستخدمة لعلاج تقلب المزاج وبعض أنواع الاكتئاب(.<br />&bull; الأدوية التي تقوم بالتحكم في الجهاز المناعي للجسم، مثل سيكلوسبورين وتاكروليمس.<br />تناول كاربازيو مع الطعام والشراب<br />يمكن تناول كاربازيو مع أو بدون الطعام .<br />قد يزيد الكحول من الآثار المهدئة ل كاربازيو. تجنب الكحول قدر الإمكان واستشر طبيبك.<br />الحمل والرضاعة والخصوبة<br />الحمل<br />إذا كنت حاملاً، أو تعتقدين أنك حاملاً أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول<br />هذا الدواء .</p><p>من المهم السيطرة على نوبات الصرع أثناء الحمل. ومع ذلك، قد يكون هناك خطر على طفلك إذا كنتي تقومين بتناول أدوية<br />مضادة للصرع أثناء الحمل. سوف يقوم طبيبك بإخبارك عن الفوائد والمخاطر المحتملة ويساعدك على أن تقرري ما إذا كان<br />يجب تناول كاربازيو.<br />لا تتوقفي عن العلاج ب تناول كاربازيو خلال فترة الحمل دون التحقق أولا مع طبيبك.<br />الرضاعة الطبيعية<br />لا يجب تناول كاربازيو مع الرضاعة الطبيعية. المادة الفعالة في كاربازيو تصل إلى لبن الثدي .<br />هذا يمكن أن يسبب أعراض جانبية للأطفال الرضع الذين يرضعون رضاعة طبيعية. اسأل طبيبك أو الصيدلي للحصول على<br />المشورة قبل تناول هذا دواء أثناء قيامك بالرضاعة الطبيعية.<br />القيادة واستخدام الآلات<br />قد يجعلك كاربازيو تشعر بالنعاس أو بالدوار أو قد يسبب عدم وضوح الرؤية أو الرؤية المزدوجة أو نقص التنسيق العضلي أو<br />انخفاض مستوى الوعي، خاصة عند بدء العلاج أو زيادة الجرعة .<br />من المهم أن تناقش مع طبيبك ما إذا كان يمكنك قيادة السيارة أو تشغيل الآلات أثناء تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائما بتناول كاربازيو تماما كما أخبرك طبيبك أو الصيدلي، حتى لو كان هذا يختلف عن المعلومات الواردة في هذه النشرة.<br />استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.<br />الجرعة المفترض تناولها<br />الجرعة للبالغين<br />&bull; جرعة البداية المعتادة من كاربازيو للبالغين )متضمنة كبار السن( هي 600 ملجم في اليوم.<br />&bull; قم بتناول قرص 300 ملجم مرتين يوميا أو قرصين 150 ملجم مرتين يوميا.<br />&bull; من الممكن أن يقوم طبيبك بزيادة الجرعة تدريجيا حتى يصل إلى الجرعة الأفضل لك. أفضل النتائج عادة ما تكون بين<br />الجرعات من 600 ملجم إلى 2,400 ملجم في اليوم .<br />&bull; إذا كنت تتناول دواء صرع أخر، الجرعة هي نفسها.<br />&bull; إذا كان لديك مرض في الكلى )مع ضعف وظيفة الكلى(، جرعة البداية ستكون هي نصف جرعة البداية المعتادة.<br />&bull; إذا كان لديك مرض كبدي حاد، قد يقوم طبيبك بتعديل الجرعة .<br />الجرعة للأطفال<br />يمكن تناول كاربازيو من قبل الأطفال الذين تتراوح أعمارهم من 6 سنوات فما فوق.<br />الجرعة في الأطفال تعتمد على وزنهم.<br />&bull; جرعة البداية هي من 8 إلى 10 ملجم/ كجم / اليوم يتم تناولها على جرعتين منفصلتين.<br />على سبيل المثال، طفل وزنه 30 كجم ستكون جرعة البداية بالنسبة له هي 150 ملجم أوكسكاربازيبين مرتين يوميا.<br />&bull; من الممكن أن يقوم طبيبك بزيادة الجرعة تدريجيا حتى يصل إلى الجرعة الأفضل لطفلك. أفضل النتائج عادة ما تكون مع<br />تناول جرعة 30 ملجم / كجم / اليوم. الجرعة القصوى للطفل هي 46 ملجم / كجم / اليوم .<br />كيفية تناول كاربازيو</p><p>&bull; ابتلاع الأقراص مع القليل من الماء.<br />&bull; إذا لزم الأمر، الأقراص يمكن كسرها في المنتصف للمساعدة في ابتلاعها. لا تقم بكسر الأقراص لتناول نصف الجرعة. لم<br />يتم تصميم خط منتصف القرص لتقسيم القرص إلى جرعات متساوية.<br />&bull; للأطفال الصغار الذين لا يستطيعون بلع الأقراص، أو الذين لا يمكن أن تعطى الجرعة اللازمة لهم في شكل أقراص،<br />أوكسكاربازيبين متاح على هيئة معلق عن طريق الفم.<br />متي وإلى متي يتم تناول كاربازيو<br />قم بتناول كاربازيو مرتين يوميا، كل يوم، في نفس الوقت تقريبا من اليوم، ما لم يخبرك الطبيب خلاف ذلك .<br />وسيكون لذلك التأثير الأفضل على السيطرة على الصرع. وسوف يساعدك أيضا على تذكر متى يؤخذ القرص )الأقراص(.<br />سوف يقوم طبيبك بإخبارك عن مدة العلاج اللازمة لك أو لطفلك بتناول كاربازيو. مدة فترة العلاج سوف تعتمد على نوعية<br />النوبات التي تحدث لك أو لطفلك. من الممكن أن يمتد العلاج لسنوات للسيطرة على النوبات. لا تقم بتغيير الجرعة أو التوقف<br />عن العلاج دون التحدث إلى طبيبك.<br />إذا تناولت كاربازيو أكثر مما يجب<br />إذا قمت بتناول عدد من الأقراص أكثر مما وصفه لك طبيبك، اتصل بأقرب مستشفى أو طبيب ك على الفور. ومن الممكن أن<br />تشمل أعراض تناول جرعة زائدة من كاربازيو:<br />&bull; النعاس، الدوخة، مشاكل في تنسيق الحركة و/ أو حركة لا إرادية للعيون، ارتعاش العضلات أو التدهور الخطير<br />للتشنجات، الصداع، فقدان الوعي، الغيبوبة.<br />&bull; الشعور بالمرض )الغثيان(، والشعور بالإعياء )القيء(، وزيادة الحركات غير المنضبطة.<br />&bull; الخمول، الرؤية المزدوجة، تضييق الجزء الأسود من العين، عدم وضوح الرؤية.<br />&bull; التعب.<br />&bull; تنفس قصير وضحل )انخفاض معدل التنفس(.<br />.)QTc &bull; عدم انتظام ضربات القلب )طول فترة<br />&bull; الارتعاش، والصداع، والغيبوبة، وانخفاض الوعي، وحركات الفم واللسان والأطراف التي لا يمكن السيطرة عليها<br />&bull; العدوان والاضطراب والارتباك.<br />&bull; انخفاضضغط الدم .<br />&bull; ضيق التنفس.<br />إذا نسيت أن تتناول كاربازيو<br />إذا كنت قد نسيت جرعة واحدة، قم بتناولها بمجرد أن تتذكر. ومع ذلك، إذا كان الوقت قريبا من تناول الجرعة التالية، لا تقم<br />بتناول الجرعة المنسية. وقم بالعودة الى الجدول الزمني الخاص بجرعاتك العادية. لا تقم بمضاعفة الجرعة في أي وقت.<br />إذا كنت غير متأكد أو قد نسيت أن تأخذ عدة جرعات، اتصل بطبيبك.<br />إذا توقفت عن تناول كاربازيو<br />لا تتوقف عن تناول الدواء ما لم يخبرك طبيبك بذلك.<br />لمنع التدهور المفاجئ للنوبات، لا تقم أبدا بالتوقف عن تناول الدواء بشكل مفاجئ.<br />إذا تم إيقاف العلاج الخاص بك، يجب أن يتم ذلك تدريجيا وفقا لتعليمات الطبيب.<br />إذا كانت لديك أي أسئلة أخرى عن تناول هذا المنتج، استشر طبيبك أو الصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، من الممكن أن يتسبب كاربازيو في أعراض جانبية، على الرغم من أنه ليس من الضروري أن تظهر على كل<br />من يتناول الدواء.<br />أخبر طبيبك على الفور أو اذهب إلى قسم الطوارئ في أقرب مستشفى إذا تعرضت لاي من الاعراض الجانبية التالية :<br />الأعراض التالية هي أعراض نادرة الحدوث )قد تؤثر على ما يصل إلى 1 من كل 10,000 شخص(: ولكنها أعراض جانبية<br />خطيرة ومن الممكن أن تتطلب معالجة طبية عاجلة. سيقرر الطبيب أيضًا ما إذا كان يجب إيقاف كاربازيو على الفور وكيفية<br />مواصلة المزيد من الرعاية الطبية<br />&bull; تورم في الشفتين والجفون والوجه والحلق أو الفم، التي يصحبها صعوبة في التنفس، الكلام أو البلع )علامات ردود فعل<br />الحساسية ووذمة وعائية( أو غيرها من علامات تفاعلات فرط الحساسية مثل الطفح الجلدي، والحمى، وألم في العضلات<br />والمفاصل.<br />&bull; ظهور تقرحات شديدة في الجلد و/ أو الأغشية المخاطية للشفاه والعينين والفم والممرات الأنفية أو الأعضاء التناسلية<br />)علامات حساسية شديدة تتضمن متلازمة ليلز ومتلازمة ستيفنز جونسون وحمامي عديدة الأشكال(.<br />&bull; التعب وضيق في التنفس عند ممارسة التمارين، مظهر شاحب، والصداع، والقشعريرة، والدوخة، والالتهابات المتكررة<br />مما يؤدي إلى الحمى، والتهاب الحلق، وتقرحات الفم، حدوث نزيف أو كدمات بسهولة أكبر من المعتاد، نزيف الأنف،<br />ظهور بقع حمراء أو ارجوانية، أو ظهور بقع غير مبررة على الجلد )دلائل على وجود انخفاض في عدد الصفائح الدموية<br />أو نقص في عدد خلايا الدم(.<br />&bull; طفح جلدي أحمر ذو شامة يظهر بشكل أساسي على الوجه والذي قد يكون مصحوبا بالتعب، والحمى، والشعور بالإعياء<br />)الغثيان( أو فقدان الشهية )علامات الذئبة الحمامية الجهازية(.<br />&bull; الخمول، والارتباك، وارتعاش العضلات أو التدهور الخطير للتشنجات )الأعراض المحتملة لانخفاض مستويات<br />الصوديوم في الدم( )انظر المحاذير والاحتياطات(.<br />&bull; أعراض تشبه الانفلونزا مع اليرقان )اصفرار الجلد أو بياض العينين( )علامات التهاب الكبد(.<br />&bull; ألم حاد في الجزء العلوي من المعدة )البطن(، والشعور بالإعياء )القيء(، وفقدان الشهية )علامات التهاب في البنكرياس(.<br />&bull; زيادة الوزن، والتعب، وفقدان الشعر، وضعف العضلات، والشعور بالبرودة )علامات نقص نشاط الغدة الدرقية( .<br />أخبر طبيبك في أقرب وقت ممكن إذا تعرضت لأي من الأعراض الجانبية التالية، فقد تتطلب عناية طبية:<br />الشائعة )قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص(<br />&bull; ارتجاف، مشاكل في تنسيق الحركة، حركة لا إرادية للعيون، القلق والعصبية، الاكتئاب، التقلبات المزاجية، الطفح الجلدي .<br />نادرة جدا )قد تؤثر على ما يصل إلى 1 من كل 10,000 شخص(<br />&bull; عدم انتظام ضربات القلب أو معدل ضربات القلب سريعة جدا أو بطيئة.<br />الأعراض الجانبية الأخرى التي قد تحدث:<br />هذه الأعراض الجانبية ل كاربازيو عادة ما تكون خفيفة إلى متوسطة. معظم هذه الأعراض تكون عابرة وعادة ما تقل مع<br />مرور الوقت.<br />شائعة جدا )قد تؤثر على أكثر من 1 من كل 10 أشخاص(<br />&bull; التعب، الصداع، الدوخة، النعاس، الشعور بالمرض )الغثيان(؛ الشعور بالإعياء )القيء(؛ الرؤية المزدوجة .<br />CARPAZIO FILM-COATED TABLETS<br />شائعة )قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص(<br />&bull; الضعف، اضطرابات الذاكرة، ضعف التركيز، اللامبالاة، الإثارة، الارتباك، عدم وضوح الرؤية، اضطرابات بصرية،<br />الإمساك، الإسهال، ألم المعدة )البطن(، حب الشباب، فقدان الشعر، واضطرابات التوازن وزيادة الوزن .<br />غير شائعة )قد تؤثر على ما يصل إلى 1 من كل 100 شخص (<br />&bull; خلايا النحل. ومن الممكن أن ترتفع مستويات إنزيمات الكبد لديك أثناء تناول كاربازيو.<br />غير معروفة )لا يمكن توقع معدلات تكرارها من المعلومات المتاحة(<br />&bull; ارتفاع ضغط الدم، اضطراب الكلام.<br />&bull; كانت هناك تقارير عن اضطرابات العظام بما في ذلك هشاشة وترقق العظام )ترقق العظام( والكسور. استشر طبيبك أو<br />الصيدلي إذا كنت مستمر في تناول دواء مضاد للصرع فترة طويلة، أو كنت ممن لديهم تاريخ من مرض هشاشة العظام أو<br />تناول الإستيرويدات.<br />الإبلاغ عن الأعراض الجانبية<br />إذا ظهرت عليك أي أعراض جانبية، قم بالتحدث مع طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي أعراض جانبية محتملة<br />غير المُدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عبر المركز الوطني للتيقظ والسلامة الدوائية.<br />يمكنك من خلال الإبلاغ عن الأعراض الجانبية أن تساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيدا عن متناول ونظر الأطفال.<br />&bull; لا يحفظ في درجة حرارة أعلي من 30 درجة مئوية.<br />&bull; لا تقم ب تناول الدواء بعد تاريخ انتهاء الصلاحية المذكور علي الشريط والعلبة. تاريخ انتهاء الصلاحية يشير إلى أخر يوم<br />في الشهر المذكور .<br />&bull; لا تقم ب تناول كاربازيو إذا لاحظت تلف العلبة أو علامات عبث بها.<br />&bull; يجب ألا يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص<br />من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة ل كاربازيو هي أوكسكاربازيبين.<br />&bull; كاربازيو 150 ملجم أقراص مغلفة بطبقة رقيقة<br />كل قرص مغلف بطبقة رقيقة يحتوي على 150 ملجم أوكسكاربازيبين.<br />&bull; كاربازيو 300 ملجم أقراص مغلفة بطبقة رقيقة<br />كل قرص مغلف بطبقة رقيقة يحتوي على 300 ملجم أوكسكاربازيبين.<br />&bull; كاربازيو 600 ملجم أقراص مغلفة بطبقة رقيقة<br />كل قرص مغلف بطبقة رقيقة يحتوي على 600 ملجم أوكسكاربازيبين.<br />&bull; المكونات الأخرى هي:</p><p>محتوي القرص: أفيسل 101 ، كروسبوفيدون إن إف، بوفيدون 30 ، أفيسل 102 ، ثاني أكسيد السيليكون الغروي وستيارات<br />الماغنسيوم.<br />إف برتقالي وماء مقطر. ǁ طبقة طلاء القرص: أوبادري 8543120</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>قرص 150 ملجم على شكل: ذات لون أصفر برتقالي، كبسول الشكل، مغلف بطبقة رقيقة ومنقوش على أحد جانبيه رقم<br />230 &quot; والجانب الأخر خالي من العلامات. &quot;<br />قرص 300 ملجم على شكل: ذات لون أصفر برتقالي، كبسول الشكل، مغلف بطبقة رقيقة ومنقوش على أحد جانبيه رقم<br />231 &quot; والجانب الأخر خالي من العلامات. &quot;<br />قرص 600 ملجم على شكل: ذات لون أصفر برتقالي، كبسول الشكل، مغلف بطبقة رقيقة ومنقوش على أحد جانبيه رقم<br />232 &quot; والجانب الأخر خالي من العلامات. &quot;<br />الأقراص المغلفة بطبقة رقيقة متاحة في عبوات تحتوي على 50 قرص مقسمة على 5 شرائط لكلا التركيزين.<br />كاربازيو أقراص مغلفة بطبقة رقيقة متوفر في ثلاثة تركيزات 150 ملجم، 300 ملجم، 600 ملجم .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك الحقوق التسويقية والمصنع<br />الدوائية<br />مصنع الأدوية بالقصيم<br />المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في أكتوبر 2020 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Carpazio® 150 mg Film-coated Tablets
Carpazio® 300 mg Film-coated Tablets
Carpazio® 600 mg Film-coated Tablets
Oxcarbazepine 150mg Film-coated Tablets
Oxcarbazepine 300mg Film-coated Tablets
Oxcarbazepine 600mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 150 mg, 300 mg or 600 mg oxcarbazepine.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.
150 mg: A yellow orange color, capsule shaped, film-coated tablet engraved with "230" on one
side and plain on the other side.
300 mg: A yellow orange color, capsule shaped, film-coated tablet engraved with "231" on one
side and plain on the other side.
600 mg: A yellow orange color, capsule shaped, film-coated tablet engraved with "232" on one
side and plain on the other side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal
doses.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carpazio&reg; is indicated for the treatment of partial seizures with or without secondarily generalised<br />tonic-clonic seizures.<br />Carpazio&reg; is indicated for use as monotherapy or adjunctive therapy in adults and in children of<br />6 years of age and above.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />In mono- and adjunctive therapy, treatment with Carpazio&reg; is initiated with a clinically effective<br />dose given in two divided doses. The dose may be increased depending on the clinical response of<br />the patient. When other antiepileptic medicinal products are replaced by Carpazio&reg;, the dose of<br />the concomitant antiepileptic medicinal product(s) should be reduced gradually on initiation of<br />Carpazio&reg; therapy. In adjunctive therapy, as the total antiepileptic medicinal product load of the<br />patient is increased, the dose of concomitant antiepileptic medicinal product(s) may need to be<br />reduced and/or the Carpazio&reg; dose increased more slowly (see section 4.5).</p><p>Therapeutic drug monitoring<br />The therapeutic effect of oxcarbazepine is primarily exerted through the active metabolite 10-<br />monohydroxy derivative (MHD) of oxcarbazepine (see section 5).<br />Plasma level monitoring of oxcarbazepine or MHD is not routinely warranted. However, may be<br />useful in situations where an alteration in MHD clearance is to be expected (see section 4.4). In<br />such situations, the dose of Carpazio&reg; may be adjusted (based on plasma levels measured 2-4<br />hours post dose) to maintain peak MHD plasma levels &lt; 35 mg/L.<br />Adults<br />Monotherapy<br />Recommended initial dose<br />Carpazio&reg; should be initiated with a dose of 600 mg/day (8-10 mg/kg/day) given in 2 divided<br />doses.<br />Maintenance dose<br />If clinically indicated, the dose may be increased by a maximum of 600 mg/day at approximately<br />weekly intervals from the starting dose to achieve the desired clinical response.<br />Therapeutic effects are seen at doses between 600 mg/day and 2,400 mg/day.<br />Controlled monotherapy trials in patients not currently being treated with antiepileptic medicinal<br />products showed 1,200 mg/day to be an effective dose; however, a dose of 2,400 mg/day has been<br />shown to be effective in more refractory patients converted from other antiepileptic medicinal<br />products to Carpazio&reg; monotherapy.<br />Maximum recommended dose<br />In a controlled hospital setting, dose increases up to 2,400 mg/day have been achieved over 48<br />hours.<br />Adjunctive therapy<br />Recommended initial dose<br />Carpazio&reg; should be initiated with a dose of 600 mg/day (8-10 mg/kg/day) given in 2 divided<br />doses.<br />Maintenance dose<br />If clinically indicated, the dose may be increased by a maximum of 600 mg/day at approximately<br />weekly intervals from the starting dose to achieve the desired clinical response.<br />Therapeutic responses are seen at doses between 600 mg/day and 2,400 mg/day.<br />Maximum recommended dose<br />Daily doses from 600 to 2,400 mg/day have been shown to be effective in a controlled adjunctive<br />therapy trial, although most patients were not able to tolerate the 2,400 mg/day dose without<br />reduction of concomitant antiepileptic medicinal products, mainly because of CNS-related adverse<br />events. Daily doses above 2,400 mg/day have not been studied systematically in clinical trials.</p><p>Elderly (65 years old and above)<br />No special dose recommendations are necessary in elderly patients because therapeutic doses are<br />individually adjusted. Dosage adjustments are recommended in elderly patients with renal<br />impairment (creatinine clearance less than 30 ml/min) (see information below on dosage in renal<br />impairment).<br />Close monitoring of sodium levels is required in patients at risk of hyponatremia (see section 4.4).<br />Patients with hepatic impairment<br />No dosage adjustment is required for patients with mild to moderate hepatic impairment.<br />Carpazio&reg; has not been studied in patients with severe hepatic impairment, therefore, caution<br />should be exercised when dosing severely impaired patients (see section 5.2).<br />Patients with renal impairment<br />In patients with impaired renal function (creatinine clearance less than 30 ml/min) Carpazio&reg;<br />therapy should be initiated at half the usual starting dose (300 mg/day) and increased, in at least<br />weekly intervals, to achieve the desired clinical response (see section 5.2).<br />Dose escalation in renally impaired patients may require more careful observation.<br />Paediatric population<br />Recommended initial dose<br />In mono- and adjunctive therapy, Carpazio&reg; should be initiated with a dose of 8-10 mg/kg/day<br />given in 2 divided doses.<br />Maintenance dose<br />In adjunctive therapy trials, a maintenance dose of 30-46 mg/kg/day, achieved over two weeks, is<br />shown to be effective and well tolerated in children. Therapeutic effects were seen at a median<br />maintenance dose of approximately 30 mg/kg/day.<br />Maximum recommended dose<br />If clinically indicated, the dose may be increased by a maximum of 10 mg/kg/day at approximately<br />weekly intervals from the starting dose, to a maximum dose of 46 mg/kg/day, to achieve the desired<br />clinical response (see section 5.2).<br />Carpazio&reg; is recommended for use in children of 6 years of age and above. Safety and efficacy<br />have been evaluated in controlled clinical trials involving approximately 230 children aged less<br />than 6 years (down to 1 month). Carpazio&reg; is not recommended in children aged less than 6 years<br />since safety and efficacy have not been adequately demonstrated.<br />All the above dosing recommendations (adults, elderly and children) are based on the doses studied<br />in clinical trials for all age groups. However, lower initiation doses may be considered where<br />appropriate.<br />Method of administration<br />The tablets are scored and can be broken into two halves in order to make it easier for the patient<br />to swallow the tablet. However, the tablet cannot be divided into equal doses. For children, who&nbsp;cannot swallow tablets or where the required dose cannot be administered using tablets,<br />oxcarbazepine oral suspension is available.<br />Carpazio&reg; can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to eslicarbazepine or to any of the excipients listed in
section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity<br />Class I (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and<br />reports of anaphylaxis have been received in the post-marketing period. Cases of anaphylaxis and<br />angioedema involving the larynx, glottis, lips and eyelids have been reported in patients after<br />taking the first or subsequent doses of Carpazio&reg;. If a patient develops these reactions after<br />treatment with Carpazio&reg;, the drug should be discontinued and an alternative treatment started.<br />Patients who have exhibited hypersensitivity reactions to carbamazepine should be informed that<br />approximately 25-30 % of these patients may experience hypersensitivity reactions (e.g. severe<br />skin reactions) with Carpazio&reg; (see section 4.8).<br />Hypersensitivity reactions, including multi-organ hypersensitivity reactions, may also occur in<br />patients without a history of hypersensitivity to carbamazepine. Such reactions can affect the skin,<br />liver, blood and lymphatic system or other organs, either individually or together in the context of<br />a systemic reaction (see section 4.8). In general, if signs and symptoms suggestive of<br />hypersensitivity reactions occur, Carpazio&reg; should be withdrawn immediately.<br />Dermatological effects<br />Serious dermatological reactions, including Stevens-Johnson syndrome, toxic epidermal<br />necrolysis (Lyell&#39;s syndrome) and erythema multiforme, have been reported very rarely in<br />association with the use of Carpazio&reg;. Patients with serious dermatological reactions may require<br />hospitalization, as these conditions may be life-threatening and very rarely be fatal. Carpazio&reg;<br />associated cases occurred in both children and adults. The median time to onset was 19 days.<br />Several isolated cases of recurrence of the serious skin reaction when rechallenged with Carpazio&reg;<br />were reported. Patients who develop a skin reaction with Carpazio&reg; should be promptly evaluated<br />and Carpazio&reg; withdrawn immediately unless the rash is clearly not drug related. In case of<br />treatment withdrawal, consideration should be given to replacing Carpazio&reg; with other<br />antiepileptic drug therapy to avoid withdrawal seizures. Carpazio&reg; should not be restarted in<br />patients who discontinued treatment due to a hypersensitivity reaction (see section 4.3).<br />HLA-B*1502 allele &ndash; in Han Chinese, Thai and other Asian populations<br />HLA-B*1502 in individuals of Han Chinese and Thai origin has been shown to be strongly<br />associated with the risk of developing the severe cutaneous reactions known as Stevens-Johnson<br />syndrome (SJS)/ toxic epidermal necrolysis (TEN) when treated with carbamazepine. The<br />chemical structure of oxcarbazepine is similar to that of carbamazepine, and it is possible that<br />patients who are positive for HLA‐B*1502 may also be at risk for SJS/TEN after treatment with<br />oxcarbazepine. There are some data that suggest that such an association exists for oxcarbazepine.<br />The prevalence of HLA-B*1502 carrier is about 10% in Han Chinese and Thai populations.Whenever possible, these individuals should be screened for this allele before starting treatment<br />with carbamazepine or a chemically-related active substance. If patients of these origins are tested<br />positive for HLA‐B*1502 allele, the use of oxcarbazepine may be considered if the benefits are<br />thought to exceed risks.<br />Because of the prevalence of this allele in other Asian populations (e.g. above 15% in the<br />Philippines and Malaysia), testing genetically at risk populations for the presence of HLA-B*1502<br />may be considered.<br />The prevalence of the HLA-B*1502 allele is negligible in e.g. European descent, African, Hispanic<br />populations sampled, and in Japanese and Koreans (&lt; 1%).<br />Allele frequencies refer to the percentage of chromosomes in the population that carry a given<br />allele. Since a person carries two copies of each chromosome, but even one copy of the HLAB*<br />1502 allele may be enough to increase the risk of SJS, the percentage of patients who may be<br />at risk is nearly twice the allele frequency.<br />HLA-A*3101 allele &ndash; European descent and Japanese populations<br />There are some data that suggest HLA-A*3101 is associated with an increased risk of<br />carbamazepine induced cutaneous adverse reactions including SJS, TEN, Drug rash with<br />eosinophilia (DRESS), or less severe acute generalized exanthematous pustulosis (AGEP) and<br />maculopapular rash in people of European descent and the Japanese.<br />The frequency of the HLA-A*3101 allele varies widely between ethnic populations. HLA-A*3101<br />allele has a prevalence of 2 to 5% in European populations and about 10% in Japanese population.<br />The presence of HLA-A*3101 allele may increase the risk for carbamazepine induced cutaneous<br />reactions (mostly less severe) from 5.0% in general population to 26.0% among subjects of<br />European ancestry, whereas its absence may reduce the risk from 5.0% to 3.8%.<br />HLA-A*3101 allele &ndash; Other descents<br />The frequency of this allele is estimated to be less than 5% in the majority of Australian, Asian,<br />African and North American populations with some exceptions within 5 to 12%. Frequency above<br />15% has been estimated in some ethnic groups in South America (Argentina and Brazil), North<br />America (US Navajo and Sioux, and Mexico Sonora Seri) and Southern India (Tamil Nadu) and<br />between 10% to 15% in other native ethnicities in these same regions.<br />Allele frequencies refer to the percentage of chromosomes in the population that carry a given<br />allele. Since a person carries two copies of each chromosome, but even one copy of the HLAA*<br />3101 allele may be enough to increase the risk of SJS, the percentage of patients who may be<br />at risk is nearly twice the allele frequency.<br />There are insufficient data supporting a recommendation for HLA-A*3101 screening before<br />starting carbamazepine or chemically-related compounds treatment.<br />If patients of European descent or Japanese origin are known to be positive for HLA-A*3101<br />allele, the use of carbamazepine or chemically-related compounds may be considered if the<br />benefits are thought to exceed risks.<br />Limitation of genetic screening</p><p>Genetic screening results must never substitute appropriate clinical vigilance and patient<br />management. Many Asian patients positive for HLA-B*1502 and treated with Carpazio&reg; will not<br />develop SJS/TEN, and patients negative for HLA-B*1502 of any ethnicity can still develop<br />SJS/TEN. The same is true for HLA-A*3101 with respect to risk of SJS, TEN, DRESS, AGEP or<br />maculopapular rash. The development of these severe cutaneous adverse reactions and its related<br />morbidity due to other possible factors such as AED dose, compliance, concomitant medications,<br />co-morbidities, and the level of dermatologic monitoring have not been studied.<br />Information for healthcare professionals<br />If testing for the presence of the HLA-B*1502 allele is performed, high-resolution &ldquo;HLA-B*1502<br />genotyping&rdquo; is recommended. The test is positive if either one or two HLA-B*1502 alleles are<br />detected, and negative if no HLA-B*1502 alleles are detected. Similarly, if testing for the presence<br />of the HLA-A*3101 allele is performed, high resolution &ldquo;HLA-A*3101 genotyping&rdquo; is<br />recommended. The test is positive if either one or two HLA-A*3101 alleles are detected, and<br />negative if no HLA-A*3101 alleles are detected.<br />Risk of seizure aggravation<br />Risk of seizure aggravation has been reported with Carpazio&reg;. The risk of seizure aggravation is<br />seen especially in children but may also occur in adults. In case of seizure aggravation, Carpazio&reg;<br />should be discontinued.<br />Hyponatraemia<br />Serum sodium levels below 125 mmol/l, usually asymptomatic and not requiring adjustment of<br />therapy, have been observed in up to 2.7 % of Carpazio&reg; treated patients. Experience from clinical<br />trials shows that serum sodium levels returned towards normal when the Carpazio&reg; dosage was<br />reduced, discontinued or the patient was treated conservatively (e.g. restricted fluid intake). In<br />patients with pre-existing renal conditions associated with low sodium levels (e.g. inappropriate<br />ADH secretion like syndrome) or in patients treated concomitantly with sodium-lowering<br />medicinal products (e.g. diuretics, desmopressin) as well as NSAIDs (e.g. indometacin), serum<br />sodium levels should be measured prior to initiating therapy. Thereafter, serum sodium levels<br />should be measured after approximately two weeks and then at monthly intervals for the first three<br />months during therapy, or according to clinical need. These risk factors may apply especially to<br />elderly patients. For patients on Carpazio&reg; therapy when starting on sodium-lowering medicinal<br />products, the same approach for sodium checks should be followed. In general, if clinical<br />symptoms suggestive of hyponatraemia occur on Carpazio&reg; therapy (see section 4.8), serum<br />sodium measurement may be considered. Other patients may have serum sodium levels assessed<br />as part of their routine laboratory studies.<br />All patients with cardiac insufficiency and secondary heart failure should have regular weight<br />measurements to determine occurrence of fluid retention. In case of fluid retention or worsening<br />of the cardiac condition, serum sodium levels should be checked. If hyponatraemia is observed,<br />water restriction is an important counter-measurement. As oxcarbazepine may, very rarely, lead to<br />impairment of cardiac conduction, patients with pre-existing conduction disturbances (e.g.<br />atrioventricular-block, arrhythmia) should be followed carefully.<br />Hypothyroidism</p><p>Hypothyroidism is an adverse reaction (with &ldquo;not known&rdquo; frequency, see section 4.8) of<br />oxcarbazepine. Considering the importance of thyroid hormones in children&#39;s development after<br />birth, thyroid function monitoring is recommended in the pediatric age group while on Carpazio&reg;<br />therapy.<br />Hepatic function<br />Very rare cases of hepatitis have been reported, which in most cases resolved favourably. When a<br />hepatic event is suspected, liver function should be evaluated and discontinuation of Carpazio&reg;<br />should be considered. Caution should be exercised when treating patients with severe hepatic<br />impairment (see section 4.2 and 5.2).<br />Renal function<br />In patients with impaired renal function (creatinine clearance less than 30 mL/min), caution should<br />be exercised during Carpazio&reg; treatment especially with regard to the starting dose and up titration<br />of the dose. Plasma level monitoring of MHD may be considered (see section 4.2 and 5.2).<br />Hematological effects<br />Very rare reports of agranulocytosis, aplastic anemia and pancytopenia have been seen in patients<br />treated with Carpazio&reg; during post-marketing experience (see section 4.8).<br />Discontinuation of the medicinal product should be considered if any evidence of significant bone<br />marrow depression develops.<br />Suicidal behaviour<br />Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in<br />several indications. A meta-analysis of randomized placebo-controlled trials of antiepileptic<br />medicines has also shown a small increased risk of suicidal ideation and behaviour. The<br />mechanism of this risk is not known and the available data do not exclude the possibility of an<br />increased risk for oxcarbazepine.<br />Therefore, patients should be monitored for signs of suicidal ideation and behaviours and<br />appropriate treatment should be considered. Patients (and caregivers of patients) should be advised<br />to seek medical advice should signs of suicidal ideation or behaviour emerge.<br />Hormonal contraceptives<br />Female patients of childbearing age should be warned that the concurrent use of Carpazio&reg; with<br />hormonal contraceptives may render this type of contraceptive ineffective (see section 4.5).<br />Additional non-hormonal forms of contraception are recommended when using Carpazio&reg;.<br />Alcohol<br />Caution should be exercised if alcohol is taken in combination with Carpazio&reg; therapy, due to a<br />possible additive sedative effect.<br />Withdrawal<br />As with all antiepileptic medicinal products, Carpazio&reg; should be withdrawn gradually to<br />minimise the potential of increased seizure frequency.<br />Monitoring of plasma levels</p><p>Although correlations between dosage and plasma levels of oxcarbazepine, and between plasma<br />levels and clinical efficacy or tolerability are rather tenuous, monitoring of the plasma levels may<br />be useful in the following situations in order to rule out noncompliance or in situations where an<br />alteration in MHD clearance is to be expected, including:<br />&bull; changes in renal function (see renal impairment in section 4.2).<br />&bull; pregnancy (see section 4.6 and 5).<br />&bull; concomitant use of liver enzyme-inducing medicines (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Enzyme induction<br />Oxcarbazepine and its pharmacologically active metabolite (the monohydroxy derivative, MHD)<br />are weak inducers in vitro and in vivo of the cytochrome P450 enzymes CYP3A4 and CYP3A5<br />responsible for the metabolism of a very large number of medicines, for example,<br />immunosuppressants (e.g. ciclosporin, tacrolimus), oral contraceptives (see below), and some<br />other antiepileptic medicinal products (e.g. carbamazepine) resulting in a lower plasma<br />concentration of these medicinal products (see table below summarizing results with other<br />antiepileptic medicinal products).<br />In vitro, oxcarbazepine and MHD are weak inducers of UDP-glucuronyl transferases (effects on<br />specific enzymes in this family are not known). Therefore, in vivo oxcarbazepine and MHD may<br />have a small inducing effect on the metabolism of medicinal products which are mainly eliminated<br />by conjugation through the UDP-glucuronyl transferases. When initiating treatment with<br />Carpazio&reg; or changing the dose, it may take 2 to 3 weeks to reach the new level of induction.<br />In case of discontinuation of Carpazio&reg; therapy, a dose reduction of the concomitant medications<br />may be necessary and should be decided upon by clinical and/or plasma level monitoring. The<br />induction is likely to gradually decrease over 2 to 3 weeks after discontinuation.<br />Hormonal contraceptives: Carpazio&reg; was shown to have an influence on the two components,<br />ethinylestradiol (EE) and levonorgestrel (LNG), of an oral contraceptive. The mean AUC values<br />of EE and LNG were decreased by 48-52 % and 32-52% respectively. Therefore, concurrent use<br />of Carpazio&reg; with hormonal contraceptives may render these contraceptives ineffective (see<br />section 4.4). Another reliable contraceptive method should be used.<br />Enzyme inhibition<br />Oxcarbazepine and MHD inhibit CYP2C19. Therefore, interactions could arise when coadministering<br />high doses of Carpazio&reg; with medicinal products that are mainly metabolised by<br />CYP2C19 (e.g. phenytoin). Phenytoin plasma levels increased by up to 40 % when Carpazio&reg;<br />was given at doses above 1,200 mg/day (see table below summarizing results with other<br />anticonvulsants). In this case, a reduction of co-administered phenytoin may be required (see<br />section 4.2).<br />Antiepileptic and enzyme inducing medicinal products<br />Potential interactions between Carpazio&reg; and other antiepileptic medicinal products were assessed<br />in clinical studies. The effect of these interactions on mean AUCs and Cmin are summarised in the<br />following table.<br />Summary of antiepileptic medicinal product interactions with Carpazio&reg;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Antiepileptic medicinal product</td><td>Influence of Carpazioon antiepileptic medicinal product</td><td>Influence of antiepileptic medicinal product on MHD</td></tr><tr><td>Co-administered</td><td>Concentration</td><td>Concentration</td></tr><tr><td>Carbamazepine</td><td>0 -22 % decrease(30 % increase of carbamazepine-epoxide)</td><td>40 % decrease</td></tr><tr><td>Clobazam</td><td>Not studied</td><td>No influence</td></tr><tr><td>Felbamate</td><td>Not studied</td><td>No influence</td></tr><tr><td>Lamotrigine</td><td>Slight decrease*</td><td>No influence</td></tr><tr><td>Phenobarbitone</td><td>14 -15 % increase</td><td>30 -31 % decrease</td></tr><tr><td>Phenytoin</td><td>0 -40 % increase</td><td>29 -35 % decrease</td></tr><tr><td>Valproic acid</td><td>Not studied</td><td>0 &ndash;18 % decrease</td></tr></tbody></table><p>Strong inducers of cytochrome P450 enzymes and/or UGT (i.e. rifampicin, carbamazepine,<br />phenytoin and phenobarbitone) have been shown to decrease the plasma/serum levels of MHD<br />(29-49 %) in adults; in children 4 to 12 years of age, MHD clearance increased by approximately<br />35% when given one of the three enzyme-inducing antiepileptic medicinal products compared to<br />monotherapy. Concomitant therapy of Carpazio&reg; and lamotrigine has been associated with an<br />increased risk of adverse events (nausea, somnolence, dizziness and headache). When one or<br />several antiepileptic medicinal products are concurrently administered with Carpazio&reg;, a careful<br />dose adjustment and/or plasma level monitoring may be considered on a case by case basis, notably<br />in paediatric patients treated concomitantly with lamotrigine.<br />No autoinduction has been observed with Carpazio&reg;.<br />Other medicinal product interactions<br />Cimetidine, erythromycin, viloxazine, warfarin and dextropropoxyphene had no effect on the<br />pharmacokinetics of MHD.<br />The interaction between oxcarbazepine and MAOIs is theoretically possible based on a structural<br />relationship of oxcarbazepine to tricyclic antidepressants.<br />Patients on tricyclic antidepressant therapy were included in clinical trials and no clinically<br />relevant interactions have been observed.<br />The combination of lithium and oxcarbazepine might cause enhanced neurotoxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential and contraceptive measures<br />Carpazio&reg; may result in a failure of the therapeutic effect of oral contraceptive medicines<br />containing ethinylestradiol (EE) and levonorgestrel (LNG) (see section 4.4 and 4.5). Women of<br />child bearing potential should be advised to use highly effective contraception (preferably nonhormonal;<br />e.g. intrauterine implants) while on treatment with Carpazio&reg;.<br />Pregnancy</p><p>Risk related to epilepsy and antiepileptic medicinal products in general:<br />In the treated population, an increase in malformations has been noted with polytherapy,<br />particularly in polytherapy including valproate.<br />Moreover, effective anti-epileptic therapy must not be interrupted, since the aggravation of the<br />illness is detrimental to both the mother and the foetus.<br />Risk related to oxcarbazepine:<br />There is moderate amount of data on pregnant women (300-1000 pregnancy outcomes). However,<br />the data on oxcarbazepine associated with congenital malformation is limited. There is no increase<br />in the total rate of malformations with Carpazio&reg; as compared with the rate observed in the general<br />population (2-3%). Nevertheless, with this amount of data, a moderate teratogenic risk cannot be<br />completely excluded.<br />Taking these data into consideration:<br />&bull; If women receiving Carpazio&reg; become pregnant or plan to become pregnant, the use of<br />this product should be carefully re-evaluated. Minimum effective doses should be given,<br />and monotherapy whenever possible should be preferred at least during the first three<br />months of pregnancy.<br />&bull; During pregnancy, an effective antiepileptic oxcarbazepine treatment must not be<br />interrupted, since the aggravation of the illness is detrimental to both the mother and the<br />foetus.<br />Monitoring and prevention:<br />Some antiepileptic medicinal products may contribute to folic acid deficiency, a possible<br />contributory cause of foetal abnormality. Folic acid supplementation is recommended before and<br />during pregnancy. As the efficacy of this supplementation is not proved, a specific antenatal<br />diagnosis should be offered even for women with a supplementary treatment of folic acid.<br />Data from a limited number of women indicate that plasma levels of the active metabolite of<br />oxcarbazepine, the 10-monohydroxy derivative (MHD), may gradually decrease throughout<br />pregnancy. It is recommended that clinical response should be monitored carefully in women<br />receiving Carpazio&reg; treatment during pregnancy to ensure that adequate seizure control is<br />maintained. Determination of changes in MHD plasma concentrations should be considered. If<br />dosages have been increased during pregnancy, postpartum MHD plasma levels may also be<br />considered for monitoring.</p><p>In the newborn child:<br />Bleeding disorders in the newborn have been reported with hepatic inductor antiepileptic<br />medicines. As a precaution, vitamin K1 should be administered as a preventive measure in the last<br />few weeks of pregnancy and to the newborn.<br />Breast-feeding<br />Oxcarbazepine and its active metabolite (MHD) are excreted in human breast milk. A milk-toplasma<br />concentration ratio of 0.5 was found for both. The effects on the infant exposed to<br />Carpazio&reg; by this route are not known. Therefore, Carpazio&reg; should not be used during breastfeeding</p><p>Fertility<br />There are no human data on fertility.<br />In rats, oxcarbazepine had no effects on fertility. Effects on reproductive parameters in female rats<br />were observed for MHD at doses comparable to those in humans (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions such as dizziness, somnolence, ataxia, diplopia, blurred vision, visual<br />disturbances, hyponatremia and depressed level of consciousness were reported with Carpazio&reg;<br />(for complete list of ADRs see section 4.8), especially at the start of treatment or in connection<br />with dose adjustments (more frequently during the up titration phase). Patients should therefore<br />exercise due caution when driving a vehicle or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The most commonly reported adverse reactions are somnolence, headache, dizziness, diplopia,<br />nausea, vomiting and fatigue occurring in more than 10% of patients.<br />The safety profile is based on adverse events from clinical trials assessed as related to Carpazio&reg;<br />. In addition, clinically meaningful reports on adverse experiences from named patient programs<br />and postmarketing experience were taken into account.<br />Adverse reactions (Table 1) are listed by MedRA system organ class.<br />Within each system organ class, the adverse reactions are ranked by frequency, with the most<br />frequent first. Within each frequency grouping, adverse reactions are presented in order of<br />decreasing seriousness. In addition, the corresponding frequency category, using the following<br />convention (CIOMS III) is also provided for each adverse reaction: very common (&ge; 1/10);<br />common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000);<br />very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).<br />Table 1 Adverse reactions</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Blood and lymphatic system disorders</td><td>&nbsp;</td></tr><tr><td><br />Uncommon</td><td>leucopenia.</td></tr><tr><td>Very rare</td><td>thrombocytopenia.</td></tr><tr><td>Unknown</td><td>bone marrow depression, aplastic anemia, agranulocytosis, pancytopenia, neutropenia.</td></tr><tr><td>mmune system disorders</td><td>&nbsp;</td></tr><tr><td>Very rare</td><td>hypersensitivity- #</td></tr><tr><td>Unknown</td><td>anaphylactic reactions</td></tr><tr><td>Endocrine disorders</td><td>&nbsp;</td></tr><tr><td>Common</td><td>weight increased.</td></tr><tr><td>Not known</td><td>hypothyroidism.</td></tr><tr><td>Metabolism and nutrition disorders</td><td>&nbsp;</td></tr><tr><td>Common</td><td>hyponatraemia</td></tr><tr><td>Unknown</td><td>Inappropriate ADH secretion like syndrome with signs and<br />symptoms of lethargy, nausea, dizziness, decrease in serum (blood)<br />osmolality, vomiting, headache, confusional state or other<br />neurological signs and symptoms..</td></tr><tr><td>Psychiatric disorders</td><td>&nbsp;</td></tr><tr><td>Common</td><td>agitation (e.g. nervousness), affect lability, confusional state,<br />depression, apathy.</td></tr><tr><td>Nervous system disorders</td><td>&nbsp;</td></tr><tr><td>Very common</td><td>somnolence, headache, dizziness.</td></tr><tr><td>Common</td><td>ataxia, tremor, nystagmus, disturbance in attention, amnesia.</td></tr><tr><td>Not known</td><td>Speech disorders (including dysarthria); more frequent during up<br />titration of Carpazio&reg; dose.</td></tr><tr><td>Eye disorders</td><td>&nbsp;</td></tr><tr><td>Very common</td><td>diplopia.</td></tr><tr><td>Common</td><td>vision blurred, visual disturbance.</td></tr><tr><td>Ear and labyrinth disorders</td><td>&nbsp;</td></tr><tr><td>Common</td><td>vertigo.</td></tr><tr><td>Cardiac disorders</td><td>&nbsp;</td></tr><tr><td>Very rare</td><td>atrioventricular block, arrhythmia.</td></tr><tr><td>Vascular disorders</td><td>&nbsp;</td></tr><tr><td>Unknown</td><td>hypertension.</td></tr><tr><td>Gastrointestinal disorders</td><td>&nbsp;</td></tr><tr><td>Very common</td><td>vomiting, nausea.</td></tr><tr><td>Common</td><td>diarrhoea, abdominal pain, constipation.</td></tr><tr><td>Very rare</td><td>pancreatitis and/or lipase and/or amylase increase</td></tr><tr><td>Hepato-biliary disorders</td><td>&nbsp;</td></tr><tr><td>Very rare</td><td>hepatitis.</td></tr><tr><td>Skin and subcutaneous tissue disorders</td><td>&nbsp;</td></tr><tr><td>Common</td><td>rash, alopecia, acne.</td></tr><tr><td>Uncommon</td><td>urticaria.</td></tr><tr><td><p>Very rare</p><p>Not known</p></td><td>Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell&#39;s<br />syndrome), angioedema, erythema multiforme (see section 4.4).<br />Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)**,<br />Acute Generalized Exanthematous Pustulosis (AGEP)**</td></tr><tr><td>Musculoskeletal, connective tissue and bone disorders</td><td>&nbsp;</td></tr><tr><td>Very rare</td><td>systemic lupus erythematosus.</td></tr><tr><td>Not known</td><td>There have been reports of decreased bone mineral density,<br />osteopenia, osteoporosis and fractures in patients on long-term<br />therapy with Carpazio&reg;. The mechanism by which Carpazio&reg;<br />affects bone metabolism has not been identified.</td></tr><tr><td>General disorders and administration site conditions</td><td>&nbsp;</td></tr><tr><td>Very common</td><td>fatigue.</td></tr><tr><td>common</td><td>asthenia.</td></tr><tr><td>Investigations</td><td>&nbsp;</td></tr><tr><td>Uncommon</td><td>hepatic enzymes increased, blood alkaline phosphatase increased</td></tr><tr><td>Unknown</td><td>decrease in T4 (with unclear clinical significance).</td></tr><tr><td>Injury, poisoning and procedural<br />complications</td><td>&nbsp;</td></tr><tr><td>Not known</td><td>Fall</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Description of selected adverse reactions<br />#Hypersensitivity (including multi-organ hypersensitivity) characterised by features such as rash,<br />fever. Other organs or systems may be affected such as blood and lymphatic system (e.g.<br />eosinophilia, thrombocytopenia, leucopenia, lymphadenopathy, splenomegaly), liver (e.g.<br />hepatitis, abnormal liver function tests), muscles and joints (e.g. joint swelling, myalgia,<br />arthralgia), nervous system (e.g. hepatic encephalopathy), kidneys (e.g. renal failure, nephritis<br />interstitial, proteinuria), lungs (e.g. pulmonary oedema, asthma, bronchospasms, interstitial lung<br />disease, dyspnea), angioedema.<br />&dagger; Serum sodium levels below 125 mmol/l have been observed in up to 2.7 % of Carpazio&reg; treated<br />patients with frequency common (see section 4.4). In most cases, the hyponatriaemia is<br />asymptomatic and does not require adjustment of therapy,<br />Very rarely, the hyponatraemia is associated with signs and symptoms such as seizures,<br />encephalopathy, depressed level of consciousness, confusion, (see also Nervous system disorders<br />for further undesirable effects), vision disorders (e.g. blurred vision), hypothyroidism, vomiting,<br />and nausea. Low serum sodium levels generally occurred during the first 3 months of treatment<br />with Carpazio&reg;, although there were patients who first developed a serum sodium level &lt;125<br />mmol/l more than 1 year after initiation of therapy (see section 4.4).<br />**Adverse reactions from spontaneous reports and literature cases (frequency not known):<br />The following adverse reactions have been derived from post-marketing experience with<br />Carpazio&reg; via spontaneous case reports and literature cases. Because these reactions are reported<br />voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency<br />which is therefore categorised as not known.<br />Reporting of suspected adverse reactions</p><p>&nbsp;</p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It<br />allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>To report any side effect(s):<br />For Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.<br />o Reporting hotline: 19999.<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa<br />For UAE:<br />Pharmacovigilance &amp; Medical Device section<br />P.O.Box: 1853<br />Tel: 80011111<br />Email: pv@mohap.gov.ae<br />Drug Department<br />Ministry of Health &amp; Prevention,<br />Dubai<br />For OMAN:<br />Department of Pharmacovigilance &amp; Drug Information<br />Directorate General of Pharmaceutical Affairs &amp; Drug Control<br />Ministry of Health, Sultanate of Oman<br />Phone Nos. 22357687 / 22357686<br />Fax: 22358489<br />Email: dg-padc@moh.gov.om<br />Website: www.moh.gov.om</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isolated cases of overdose have been reported. The maximum dose taken was approximately<br />48,000 mg.<br />Symptoms<br />Electrolyte and fluid balance conditions: hyponatraemia</p><p>Eye disorders: diplopia, miosis, blurred vision<br />Gastrointestinal disorders: nausea, vomiting, hyperkinesia<br />General disorders and administration site conditions: fatigue<br />Investigations: respiratory rate depression, QTc prolongation<br />Nervous system disorders: drowsiness and somnolence, dizziness, ataxia and nystagmus, tremor,<br />disturbances in coordination (coordination abnormal), convulsion, headache, coma, loss of<br />consciousness, dyskinesia<br />Psychiatric disorders: aggression, agitation, confusional state<br />Vascular disorders: hypotension<br />Respiratory, thoracic and mediastinal disorders: dyspnoea<br />Management<br />There is no specific antidote. Symptomatic and supportive treatment should be administered as<br />appropriate. Removal of the medicinal product by gastric lavage and/or inactivation by<br />administering activated charcoal should be considered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiepileptics, ATC code: N03A F 02<br />Pharmacodynamic effects<br />The pharmacological activity of oxcarbazepine is primarily exerted through the metabolite (MHD)<br />(see section 5.2). The mechanism of action of oxcarbazepine and MHD is thought to be mainly<br />based on the blockade of voltage-sensitive sodium channels, thus resulting in stabilisation of<br />hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminishment of<br />propagation of synaptic impulses. In addition, increased potassium conductance and modulation<br />of high-voltage activated calcium channels may also contribute to the anticonvulsant effects. No<br />significant interactions with brain neurotransmitter or modulator receptor sites were found.<br />Oxcarbazepine and its active metabolite (MHD), are potent and efficacious anticonvulsants in<br />animals. They protected rodents against generalised tonic-clonic and, to a lesser degree, clonic<br />seizures, and abolished or reduced the frequency of chronically recurring partial seizures in Rhesus<br />monkeys with aluminum implants. No tolerance (i.e. attenuation of anticonvulsive activity) against<br />tonic-clonic seizures was observed when mice and rats were treated daily for 5 days or 4 weeks,<br />respectively, with oxcarbazepine or MHD.<br />A prospective, open label, multicentre, non-comparative, 24 week observational post marketing<br />study has been conducted in India. Out of a study population of 816 patients, 256 pediatric patients<br />(1 month to 19 years) with generalised tonic-clonic seizures (either secondary or primary) were<br />treated with oxcarbazepine monotherapy. The initial oxcarbazepine dose for all patients &gt; 6 years<br />was 8-10 mg/kg/day given in 2 divided doses. For the 27 subjects aged 1 month to 6 years, the<br />dose range for the initial dose was 4.62 - 27.27 mg/kg/day and 4.29 - 30.00 mg/kg/day maintenance<br />dose. The primary endpoint was reduction in seizure frequency from baseline at week 24. In the&nbsp;age group 1 month to 6 years (n=27) the number of seizures changed from 1 [range] [1-12] to 0<br />[0-2], in the age group 7 years to 12 years (n=77) the frequency changed from 1 [1-22] to 0 [0-1]<br />and in the age group 13-19 years (n=152), the frequency changed from 1 [1-32] to 0 [0-3]. No<br />specific safety concerns in the pediatric patients were identified. Data supporting benefit/risk from<br />the study regarding children under the age of 6 are inconclusive (see section 4.2).<br />Based on the data from the randomized controlled trials, the use of oxcarbazepine is not<br />recommended in children below the age of 6 since safety and efficacy have not been adequately<br />demonstrated (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Following oral administration of Carpazio&reg;, oxcarbazepine is completely absorbed and<br />extensively metabolised to its pharmacologically active metabolite (MHD).<br />After single dose administration of 600 mg Carpazio&reg; to healthy male volunteers under fasted<br />conditions, the mean Cmax value of MHD was 34 &mu;mol/l, with a corresponding median tmax of 4.5<br />hours.<br />In a mass balance study in man, only 2 % of total radioactivity in plasma was due to unchanged<br />oxcarbazepine, approximately 70 % was due to MHD, and the remainder attributable to minor<br />secondary metabolites which were rapidly eliminated.<br />Food has no effect on the rate and extent of absorption of oxcarbazepine, therefore, Carpazio&reg; can<br />be taken with or without food.<br />Distribution<br />The apparent volume of distribution of MHD is 49 litres.<br />Approximately 40 % of MHD, is bound to serum proteins, predominantly to albumin. Binding was<br />independent of the serum concentration within the therapeutically relevant range. Oxcarbazepine<br />and MHD do not bind to alpha-1-acid glycoprotein.<br />Oxcarbazepine and MHD cross the placenta. Neonatal and maternal plasma MHD concentrations<br />were similar in one case.<br />Biotransformation<br />Oxcarbazepine is rapidly reduced by cytosolic enzymes in the liver to MHD, which is primarily<br />responsible for the pharmacological effect of Carpazio&reg;. MHD is metabolised further by<br />conjugation with glucuronic acid. Minor amounts (4 % of the dose) are oxidised to the<br />pharmacologically inactive metabolite (10, 11-dihydroxy derivative, DHD).<br />Elimination<br />Oxcarbazepine is cleared from the body mostly in the form of metabolites which are predominantly<br />excreted by the kidneys. More than 95 % of the dose appears in the urine, with less than 1 % as<br />unchanged oxcarbazepine. Faecal excretion accounts for less than 4 % of the administered dose.<br />Approximately 80 % of the dose is excreted in the urine either as glucuronides of MHD (49 %) or&nbsp;&nbsp;as unchanged MHD (27 %), whereas the inactive DHD accounts for approximately 3 % and<br />conjugates of oxcarbazepine account for 13 % of the dose.<br />Oxcarbazepine is rapidly eliminated from the plasma with apparent half-life values between 1.3<br />and 2.3 hours. In contrast, the apparent plasma half-life of MHD averaged 9.3 &plusmn; 1.8 h.<br />Dose proportionality<br />Steady-state plasma concentrations of MHD are reached within 2 - 3 days in patients when<br />Carpazio&reg; is given twice a day. At steady-state, the pharmacokinetics of MHD are linear and show<br />dose proportionality across the dose range of 300 to 2,400 mg/day.<br />Special populations<br />Patients with hepatic impairment<br />The pharmacokinetics and metabolism of oxcarbazepine and MHD were evaluated in healthy<br />volunteers and hepatically-impaired subjects after a single 900 mg oral dose. Mild to moderate<br />hepatic impairment did not affect the pharmacokinetics of oxcarbazepine and MHD. Carpazio&reg;<br />has not been studied in patients with severe hepatic impairment.<br />Patients with renal impairment<br />There is a linear correlation between creatinine clearance and the renal clearance of MHD. When<br />Carpazio&reg; is administered as a single 300 mg dose, in renally impaired patients (creatinine<br />clearance &lt; 30 mL/min) the elimination half-life of MHD is prolonged by 60-90 % (16 to 19 hours)<br />with a two fold increase in AUC compared to adults with normal renal function (10 hours).<br />Children<br />The pharmacokinetics of Carpazio&reg; were evaluated in clinical trials in paediatric patients taking<br />Carpazio&reg; in the dose range 10-60 mg/kg/day. Weight-adjusted MHD clearance decreases as age<br />and weight increases approaching that of adults. The mean weight-adjusted clearance in children<br />4 to 12 years of age is approximately 40% higher than that of adults. Therefore, MHD exposure in<br />these children is expected to be about two-thirds that of adults when treated with a similar weightadjusted<br />dose. As weight increases, for patients 13 years of age and above, the weight-adjusted<br />MHD clearance is expected to reach that of adults.<br />Pregnancy<br />Data from a limited number of women indicate that MHD plasma levels may gradually decrease<br />throughout pregnancy (see section 4.6).<br />Elderly<br />Following administration of single (300 mg) and multiple doses (600 mg/day) of Carpazio&reg; in<br />elderly volunteers (60 - 82 years of age), the maximum plasma concentrations and AUC values of<br />MHD were 30 % - 60 % higher than in younger volunteers (18 - 32 years of age). Comparisons of<br />creatinine clearances in young and elderly volunteers indicate that the difference was due to agerelated<br />reductions in creatinine clearance. No special dose recommendations are necessary because<br />therapeutic doses are individually adjusted.<br />Gender&nbsp;No gender related pharmacokinetic differences have been observed in children, adults, or the<br />elderly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data indicated no special hazard for humans based on safety pharmacology and<br />genotoxicity studies with oxcarbazepine and the pharmacologically active metabolite,<br />monohydroxy derivative (MHD).<br />Evidence of nephrotoxicity was noted in repeated dose toxicity rat studies but not in dog or mice<br />studies.<br />Immunotoxicity<br />Immunostimulatory tests in mice showed that MHD (and to a lesser extent oxcarbazepine) can<br />induce delayed hypersensitivity.<br />Mutagenicity<br />Oxcarbazepine increased mutation frequencies in one Ames test in vitro in the absence of<br />metabolic activation in one of five bacterial strains. Oxcarbazepine and MHD produced increases<br />in chromosomal aberrations and/or polyploidy in the Chinese hamster ovary assay in vitro in the<br />absence of metabolic activation. MHD was negative in the Ames test, and no mutagenic or<br />clastogenic activity was found with either oxcarbazepine or MHD in V79 Chinese hamster cells<br />in vitro. Oxcarbazepine and MHD were both negative for clastogenic or aneugenic effects<br />(micronucleus formation) in an in vivo rat bone marrow assay.<br />Reproductive toxicity<br />In rats, fertility in both sexes was unaffected by oxcarbazepine at oral doses up to 150 mg/kg/day,<br />at which there is no safety margin. Disruption of estrous cyclicity and reduced numbers of corpora<br />lutea, implantations and live embryos were observed in female animals for MHD at doses<br />comparable to those in humans (see section 4.6).<br />Standard reproductive toxicity studies in rodents and rabbits revealed effects such as increases in<br />the incidence of embryo-foetal mortality and/or some delay in antenatal and/or postnatal growth<br />of the offspring at maternally toxic dose levels. There was an increase in rat foetal malformations<br />in one of the eight embryo-foetal toxicity studies, which were conducted with either oxcarbazepine<br />or MHD, at doses which also caused maternal toxicity (see section 4.6).<br />Carcinogenicity<br />In the carcinogenicity studies, liver (rats and mice), testicular and female genital tract granular cell<br />(rats) tumours were induced in treated animals. The occurrence of liver tumours was most likely a<br />consequence of the induction of hepatic microsomal enzymes; an inductive effect which, although<br />it cannot be excluded, is weak or absent in patients treated with Carpazio&reg; . Testicular tumours<br />may have been induced by elevated luteinizing hormone concentrations. Due to the absence of<br />such an increase in humans, these tumours are considered to be of no clinical relevance. A doserelated<br />increase in the incidence of granular cell tumours of the female genital tract (cervix and<br />vagina) was noted in the rat carcinogenicity study with MHD. These effects occurred at exposure<br />levels comparable with the anticipated clinical exposure. The mechanism for the development of&nbsp;these tumours has not been fully elucidated but could be related to increased estradiol levels<br />specific to the rat. The clinical relevance of these tumours is unclear.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For Carpazio 150mg:<br />Tablet core:<br />Avicel 101: 5.00 mg<br />Crospovidone NF: 32.00 mg<br />Povidone 30: 6.00 mg<br />Avicel 102: 3.00 mg<br />Colloidal Silicon Dioxide: 2.00 mg<br />Magnesium Stearate: 2.00 mg<br />Tablet coating:<br />Opadry II 85F43120 Orange: 4.00 mg<br />Purified Water q.s.<br />For Carpazio 300mg:<br />Tablet core:<br />Avicel 101: 10.00 mg<br />Crospovidone NF: 64.00 mg<br />Povidone 30: 12.00 mg<br />Avicel 102: 6.00 mg<br />Colloidal Silicon Dioxide: 4.00 mg<br />Magnesium Stearate: 4.00 mg<br />Tablet coating:<br />Opadry II 85F43120 Orange: 8.00 mg<br />Purified water q.s.<br />For Carpazio 600mg:<br />Tablet core:<br />Avicel 101: 20.00 mg<br />Crospovidone NF: 128.00 mg<br />Povidone 30: 24.00 mg<br />CARPAZIO FILM-COATED TABLETS<br />Avicel 102: 12.00 mg<br />Colloidal Silicon Dioxide: 8.00 mg<br />Magnesium Stearate: 8.00 mg<br />Tablet coating:<br />Opadry II 85F43120 Orange: 16.00 mg<br />Purified water q.s.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months/2 Years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister type: White opaque PVC/PE/PVDC with hard tempered aluminium foil lid.<br />Tablets 150 mg: blister pack of 50 tablets divided into 5 blisters.<br />Tablets 300 mg: blister pack of 50 tablets divided into 5 blisters.<br />Tablets 600 mg: blister pack of 50 tablets divided into 5 blisters.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No Special Disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2020.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>